Clinical Study on the Mass Balance of Clifutinib

Phase 1 Completed 6 enrolled Sunshine Lake Pharma Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\]Clifutinib, the distribution of total radioactivity in whole blood and plasma, and to determine the main excretion and metabolic pathways.

Timeline

Start: 2025-09-29
Primary completion: 2025-11-05
Completion: 2025-11-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clifutinib	Unknown	40 mg	Oral

Indications

No indication recorded.